Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Inclusion Criteria: * Have no history of Adalimumab and cell-depleting biologics * Have no history of any other biologics use within 6 months prior to Week 0 * Have plaque psoriasis diagnosed at least 6 months, with or without psoriatic arthritis * Have plaque psoriasis with the involvement and severity of total affected BSA ≥ 10%, PASI score of ≥ 12 and PGA score of ≥ 3 (moderate) * Considered to be a candidate for phototherapy or systemic therapy for psoriasis * Adequate hematological, renal, and hepatic function by central lab * Non-childbearing potential female, or childbearing potential female subjects or male subjects with their partners who agree to use at least two forms of appropriate contraception method from Screening until 5 months after the last dose of IP Exclusion Criteria: * Have nonplaque forms of psoriasis, including erythrodermic, pustular, guttate, or drug-induced psoriasis * Have other skin disease than psoriasis that requires topical, phototherapy or systemic therapy * Known allergic reactions or hypersensitivity to adalimumab or to any ingredients of SB5 or Humira * Have received phototherapy or conventional systemic therapy within 4 weeks prior to Week 0 * Have received topical therapy for psoriasis within 2 weeks prior to Week 0, however class 6/7 corticosteroids are allowed on face and groin * Women who are pregnant or nursing at Screening, or men and women planning pregnancy during the study period and until 5 months after the last dose of IP * Have received a live or live attenuated viral vaccine or a live bacterial vaccine within 8 weeks prior to Week 0. Non-live COVID-19 vaccines are allowed * Have active or latent tuberculosis * History of ongoing infection or a positive test of HBV, HCV, or HIV infection * History of sepsis, chronic or recurrent infection * History of lymphoproliferative disease or leukaemia * History of malignancy within the last 5 years